

XDNA

Kelly CRISPR & Gene Editing Technology ETF

Analyst Report

XDNA tracks a market-cap-weighted index of companies in developed markets that focus on the advancements in DNA modification technology.

ESG Themes and Scores

6.04/10

ESG Rate

39.71%

Global Percentile

36.67%

Peer Percentile

Performance Data

	XDNA	ETF Database Category Average	Factset Segment Average
1 Month	-16.87%	-7.85%	-8.44%
3 Month	-34.54%	-16.86%	-17.27%
YTD Return	-38.03%	-14.59%	-19.02%
1 Year Return	-48.24%	-14.01%	-24.12%
3 Year Return	N/A	-5.51%	0.00%
5 Year Return	N/A	1.30%	0.00%

Top 5 Holdings

Symbol	Holding	% Assets
BEAM	Beam Therapeutics, Inc.	11.10%
TMO	Thermo Fisher Scientific Inc.	10.47%
CRSP	CRISPR Therapeutics AG	10.41%
NTLA	Intellia Therapeutics, Inc.	8.66%
PRME	Prime Medicine, Inc.	6.16%

Vitals

Issuer	Kelly Intelligence LLC
Brand	Kelly
Structure	ETF
Expense Ratio	0.78%
Inception	Jan 12, 2022
Index Tracked	Strategic CRISPR & Gene Editing Technology Index - Benchmark TR Gross

ETF Database Themes

Category	Health & Biotech Equities
Asset Class	Equity
Asset Class Size	Multi-Cap
Asset Class Style	Growth
Region (General)	Developed Markets
Region (Specific)	Broad

FactSet Classifications

Segment	Equity: Developed Markets Pharma, Biotech & Life Sciences
Category	Sector
Focus	Health Care
Niche	Pharma, Biotech & Life Sciences
Strategy	Vanilla
Weighting	Market Cap

